McGuireWoods is expanding its patent litigation capabilities with the addition of New York partners Benjamin Hsing, Wanda French-Brown and Irene Hudson, who bring a wealth of patent litigation experience for life sciences industry clients. All three join McGuireWoods from BakerHostetler.
Hsing, French-Brown and Hudson represent pharmaceutical companies in patent matters involving Hatch-Waxman Abbreviated New Drug Applications (ANDA). They also advise technology, biotechnology and medical device companies.
“Ben, Wanda and Irene are highly respected for devising strategies to help domestic and international companies navigate complex patent litigation challenges,” said David Finkelson, chair of the firm’s Intellectual Property & Patent Litigation Department.
“Their skill in ANDA-based litigation, in particular, will be an important asset for our healthcare and life sciences clients,” added Holly Buckley, co-leader of the firm’s healthcare and life sciences industry team.
A former patent examiner, Hsing has tried numerous high-profile cases on behalf of major pharmaceutical and technology companies and has conducted intellectual property due diligence investigations for acquisitions and licensing deals. LMG Life Sciences named Hsing New York’s 2017 Patent Strategy Management Attorney of the Year and Chambers USA has ranked him for intellectual property each year since 2013.
French-Brown has represented life sciences industry companies in patent litigation cases involving pharmaceuticals (Hatch-Waxman), healthcare diagnostics, medical devices, food chemistry and biotechnology. French-Brown’s background includes a decade as a registered pharmacist. She advises clients on Food and Drug Administration guidelines governing the entry of generic and biosimilar pharmaceutical products. She also counsels pharmaceutical clients on the scope and coverage of new patents, new drug product exclusivity and litigation strategy.
Hudson advises Fortune 500 companies, large corporations and emerging pharmaceutical companies and has significant experience coordinating multijurisdictional litigation. She represents clients in multipatent and multidefendant cases domestically and internationally, manages worldwide trademark portfolios and handles trademark and trade dress infringement litigation.
“We’re delighted to welcome Ben, Wanda and Irene,” said Noreen Kelly, managing partner of the firm’s New York office. “They enhance our client service capabilities nationally and continue our growth in New York.”
McGuireWoods’ healthcare and life sciences industry team delivers integrated services to companies that develop, manufacture and distribute pharmaceuticals, medical devices and biological products. In intellectual property matters, the firm’s coordinated team of trial and transactional lawyers handle bet-the-company litigation, counseling, competitor patent monitoring, licensing and patent prosecution. The firm earned a “standout” rating for IP litigation in the 2019 edition of BTI Litigation Outlook based on feedback from corporate counsel.
Source: www.mcguirewoods.com
